Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval

2021-07-06

Page View：

Recently, a recombinant humanized anti-MUC1 monoclonal antibody-Tub201 coupling agent (hereinafter referred to as "Muc1") for the treatment of advanced solid tumor class 1 ADC drug injection from Dac Biotechnology was approved for clinical use. This is the first clinically approved Muc1-ADC drug in China.

Shanghai Medicilon has provided a full set of preclinical research services including pharmacology, pharmacokinetics and safety evaluation in the research and development of new Muc1 drugs, helping the project to be successfully approved for clinical trials.

Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval.webp

ADC drugs have the characteristics of heterogeneity, complex metabolic pathways in vivo, and diverse metabolic active substances. The research and development involves antibodies, cytotoxins, and chemical coupling technologies. Therefore, the technical barriers to R&D of ADCs are much higher than other drugs, and they face many difficulties and challenges.

Aiming at the dilemma of Muc1 "there is no relevant animal species, and it is almost impossible to study alternative molecules and select transgenic animals, how to analyze test data and evaluate human safety?", Medicilon and Dac Biotechnology’s personnel learned the lessons of early ADC drug development and safety evaluation and the new requirements of domestic and foreign regulatory agencies for ADC drug safety evaluation in recent years, combined with years of practical experience and technology in ADC drug safety evaluation, and finally overcome the difficulties. In addition, Medicilon has also innovatively designed a variety of original small molecule/linker and original antibody toxicity experiments to provide customers with more choices and fully guarantee the strict, orderly, high-quality, and efficient testing of MUC1-ADC drugs. Research and development has been highly recognized by Dac Biotechnology.

As a strategic partner, Medicilon's antibody-drug conjugate (ADC) preclinical R&D platform provides customized one-stop preclinical research services for Dac Biotechnology, strictly ensuring the safety and quality of new drugs, and has successfully assisted Dac Biotechnology 5 sets of ADC projects to be under pre-clinical research and development, and several ADC projects to be under development.

Medicilon congratulates Dac Biotechnology MUC1 on its phased success, and hopes that MUC1 will be launched as soon as possible to bring good news to patients with advanced solid tumors.

ADC Muc1-ADC

Return

Relevant news

ADC, precision and deep cultivation for targeted drug delivery

2022-08-01

Antibody conjugate (ADC) is the focus of tumor therapy research in recent years. Because of its good targeting and obvious clinical efficacy, ADC has become the frontier of antibody drug research and development and is one of the strategic focuses of new drug research and development in China.

ADC research and development are normalizing, but Pfizer "quietly” changed hands to others!

2021-04-27

On March 18, Pfizer and American biotechnology company Pyxis Oncology (hereinafter referred to as "Pyxis”) jointly announced that the two parties have reached a global licensing agreement for two ADC (antibody-drug conjugate) candidate products, but specific transactions The amount was not disclosed. According to the license agreement, Pfizer will provide Pyxis with worldwide licensing, developmentRead more

The main points of clinical use of 8 ADC drugs

2021-04-27

Antibody-Drug Conjugate (ADC) is a class of targeted biological agents that conjugate target-specific monoclonal antibodies to highly lethal cytotoxic drugs through a specific connector.Small molecule cytotoxic drugs can be efficiently delivered to target tumor cells by using monoclonal antibodies as the carrier.